Which previously treated neuroendocrine tumor populations were included in the final label?
YOUR PRIVATE STARTING POINT
Compare with what you saved.
Save a milestone to your account’s Notebook. Reopen its original snapshot here and compare with this reviewed catalog. Email subscriptions use a separate opt-in.
Exelixis reported FDA review of the supplemental application for previously treated advanced neuroendocrine tumors, with an April 3, 2025 target action date.
Exelixis announced FDA approval of CABOMETYX for specified previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumors. The approval announcement preceded the published target date.
These selected company announcements preserve publication dates separately from ORION’s later recording times. Registry completion dates and follow-up research questions are separate from company announcements; this historical release does not establish current guidance or continuous monitoring.